Skip to main content
REGN
NASDAQ Life Sciences

Regeneron-Licensed Obesity Drug Olatorepatide Delivers Up to 19% Weight Loss in Positive Phase 3 China Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$741.98
Mkt Cap
$80.319B
52W Low
$476.487
52W High
$821.11
52W Position info
56% above low
Off High info
9.6% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

REGN sits 56% above its 52-week low of $476.487.

Summary

Regeneron announced positive topline Phase 3 results for olatorepatide, a dual GLP-1/GIP receptor agonist licensed by the company, from a trial conducted in Chinese patients. The drug demonstrated significant efficacy, with participants achieving up to 19% mean body weight loss at week 48, and exhibited a favorable gastrointestinal tolerability profile compared to other dual incretin trials. This positive clinical update follows a recent positive opinion from the European Medicines Agency for another Regeneron product, and provides a strong counterpoint to general concerns about pipeline regulatory delays mentioned in the company's recent 10-K. These robust results position olatorepatide as a potentially competitive entrant in the high-value obesity market, with Regeneron holding exclusive development and commercial rights outside of Greater China. The company plans to initiate its global Phase 3 registrational program later this year, and investors will be closely watching its progress and further data presentations.

At the time of this announcement, REGN was trading at $741.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.3B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

REGN - Latest Insights

REGN
Nov 18, 2026, 6:06 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $942.00
Real-time Price: $920.59 info
Change: -$21.41 (-2%) info
Market Cap: $95.228B info
REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $920.59 info
Change: +$20.59 (+2%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $920.59 info
Change: +$10.07 (+1%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $920.59 info
Change: +$64.59 (+8%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $920.59 info
Change: +$85.59 (+10%) info
Market Cap: $95.228B info